These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 8630291

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical pharmacokinetics of topotecan.
    Herben VM, ten Bokkel Huinink WW, Beijnen JH.
    Clin Pharmacokinet; 1996 Aug; 31(2):85-102. PubMed ID: 8853931
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
    Creemers GJ, Gerrits CJ, Eckardt JR, Schellens JH, Burris HA, Planting AS, Rodriguez GI, Loos WJ, Hudson I, Broom C, Verweij J, Von Hoff DD.
    J Clin Oncol; 1997 Mar; 15(3):1087-93. PubMed ID: 9060549
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.
    Wall JG, Burris HA, Von Hoff DD, Rodriguez G, Kneuper-Hall R, Shaffer D, O'Rourke T, Brown T, Weiss G, Clark G.
    Anticancer Drugs; 1992 Aug; 3(4):337-45. PubMed ID: 1330081
    [Abstract] [Full Text] [Related]

  • 8. The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
    Gerrits CJ, Schellens JH, Creemers GJ, Wissel P, Planting AS, Pritchard JF, DePee S, de Boer-Dennert M, Harteveld M, Verweij J.
    Br J Cancer; 1997 Aug; 76(7):946-51. PubMed ID: 9328158
    [Abstract] [Full Text] [Related]

  • 9. Oral topotecan: bioavailablity and effect of food co-administration.
    Herben VM, Rosing H, ten Bokkel Huinink WW, van Zomeren DM, Batchelor D, Doyle E, Beusenberg FD, Beijnen JH, Schellens JH.
    Br J Cancer; 1999 Jul; 80(9):1380-6. PubMed ID: 10424739
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.
    Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, Smith BR, Hurowitz L, DeLisa A, Donehower RC.
    Drug Metab Dispos; 1992 Jul; 20(5):706-13. PubMed ID: 1358575
    [Abstract] [Full Text] [Related]

  • 11. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors.
    Zamboni WC, Bowman LC, Tan M, Santana VM, Houghton PJ, Meyer WH, Pratt CB, Heideman RL, Gajjar AJ, Pappo AS, Stewart CF.
    Cancer Chemother Pharmacol; 1999 Jul; 43(6):454-60. PubMed ID: 10321504
    [Abstract] [Full Text] [Related]

  • 12. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
    Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JH.
    J Clin Oncol; 2002 Jul 01; 20(13):2943-50. PubMed ID: 12089223
    [Abstract] [Full Text] [Related]

  • 13. An overview of the clinical pharmacology of topotecan.
    Dennis MJ, Beijnen JH, Grochow LB, van Warmerdam LJ.
    Semin Oncol; 1997 Feb 01; 24(1 Suppl 5):S5-12-S5-18. PubMed ID: 9122737
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
    Gelderblom H, Salazar R, Verweij J, Pentheroudakis G, de Jonge MJ, Devlin M, van Hooije C, Seguy F, Obach R, Pruñonosa J, Principe P, Twelves C.
    Clin Cancer Res; 2003 Sep 15; 9(11):4101-7. PubMed ID: 14519632
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.
    Verweij J, Lund B, Beijnen J, Planting A, de Boer-Dennert M, Koier I, Rosing H, Hansen H.
    Ann Oncol; 1993 Sep 15; 4(8):673-8. PubMed ID: 8240998
    [Abstract] [Full Text] [Related]

  • 18. Clinical, pharmacokinetic and biological studies of topotecan.
    O'Dwyer PJ, LaCreta FP, Haas NB, Halbherr T, Frucht H, Goosenberg E, Yao KS.
    Cancer Chemother Pharmacol; 1994 Sep 15; 34 Suppl():S46-52. PubMed ID: 8070027
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
    Rowinsky EK, Grochow LB, Sartorius SE, Bowling MK, Kaufmann SH, Peereboom D, Donehower RC.
    J Clin Oncol; 1996 Apr 15; 14(4):1224-35. PubMed ID: 8648378
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.